Prospective, Randomized Study of Oral Metronidazole vs. Oral Metronidazole and Rifampin for Treatment of Clostridium Difficile-associated Diarrhea (CDAD)

NCT00182429 Phase 3 COMPLETED

What is the difference between the use of one drug (Oral Metronidazole) versus the use of this same drug combined with another drug (Rifampin) in treatment of bacteria and infection-associated diarrhea in patients? This infection is an important cause of morbidity and mortality in both the community and hospitals, and the leading cause of hospital and chronic facility-acquired diarrhea. Research is important for the treatment of this infection. Patient care with use of two medication treatment regimens will be studied.

Details

Lead sponsor	McMaster University
Phase	Phase 3
Status	COMPLETED
Enrolment	100
Start date	2004-02
Completion	2005-12-31

Conditions

• Clostridium Enterocolitis
• Antibiotic-Associated Diarrhea
• Pseudomembranous Colitis
• Pseudomembranous Enterocolitis
• Pseudomembranous Enteritis

Interventions

• Metronidazole and Rifampin

Primary outcomes

• Resolution of symptoms in each treatment arm (in days) up to 40 days (measured using daily stool and symptom diary).

Countries

Canada